Palatin Technologies (PTN) Change in Receivables (2010 - 2025)
Palatin Technologies' (PTN) quarterly Change in Receivables came in at -$5.3 million in Q4 2025, down 176.24% quarter-over-quarter from $6.9 million in Q3 2025.
Analysis
Palatin Technologies (PTN) Change in Receivables (2010 - 2025) Analysis & Trends
Palatin Technologies (PTN) has reported Change in Receivables for 13 consecutive years, with -$5.3 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Change in Receivables changed N/A year-over-year to -$5.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (up 169.74% YoY), and the FY2024 full-year result was -$2.9 million, down 156.73% from the prior year.
- Change in Receivables eased to -$5.3 million in Q4 2025 per PTN's latest filing, from $6.9 million in the prior quarter.
- Across five years, Change in Receivables topped out at $6.9 million in Q3 2025 and bottomed at -$5.3 million in Q4 2025.
- Historically, Change in Receivables has averaged -$98728.8 across 5 years, with a median of $107880.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables soared 745.68% in 2023, then sank 2274.79% in 2024.
- Over 5 years, Change in Receivables stood at -$1.7 million in 2021, then surged by 112.98% to $215760.0 in 2022, then tumbled by 1090.39% to -$2.1 million in 2023, then slipped by 9.8% to -$2.3 million in 2024, then sank by 123.77% to -$5.3 million in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered -$5.3 million, $6.9 million, and -$2.3 million for Q4 2025, Q3 2025, and Q1 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -5.25 Mn |
| Sep 30, 2025 | 6.89 Mn |
| Mar 31, 2024 | -2.35 Mn |
| Dec 31, 2023 | -2.14 Mn |
| Sep 30, 2023 | 1.57 Mn |
| Jun 30, 2023 | -1.22 Mn |
| Mar 31, 2023 | 107,880.00 |
| Dec 31, 2022 | 215,760.00 |
| Sep 30, 2022 | -242,730.00 |
| Jun 30, 2022 | 590,861.00 |
| Mar 31, 2022 | 206,014.00 |
| Dec 31, 2021 | -1.66 Mn |
| Sep 30, 2021 | 666,428.00 |
| Jun 30, 2021 | 3.45 Mn |
| Mar 31, 2021 | -2.32 Mn |
| Dec 31, 2020 | 1.19 Mn |
| Sep 30, 2020 | -744,372.00 |
| Jun 30, 2020 | 120.53 Mn |
| Mar 31, 2020 | -117,989.00 |
| Dec 31, 2019 | 20,610.00 |